中华风湿病学杂志
中華風濕病學雜誌
중화풍습병학잡지
CHINESE JOURNAL OF RHEUMATOLOGY
2010年
3期
165-167,后插1
,共4页
穆荣%蒋慧蓉%李玉宾%Iain B McIness%栗占国
穆榮%蔣慧蓉%李玉賓%Iain B McIness%慄佔國
목영%장혜용%리옥빈%Iain B McIness%률점국
白细胞介素类%关节炎%实验性%关节炎%类风湿
白細胞介素類%關節炎%實驗性%關節炎%類風濕
백세포개소류%관절염%실험성%관절염%류풍습
lnterleukins%Arthritis%experimental%Arthritis%rheumatoid
目的 探讨新型细胞因子自细胞介素(IL)-33在胶原诱导性关节炎(CIA)发病中的作用.方法 建它DBA/1小鼠的CIA模型.以牛Ⅱ型胶原(CⅡ)/完全福氏佐剂(CFA)免疫,从免疫后第21天开始每天注射IL-33或磷酸盐缓冲液(PBS)共5 d.免疫后第28天取小鼠淋巴结细胞体外培养,培养上清的细胞因子浓度以酶联免疫吸附试验(ELISA)法检测或Luminex检测.同时检测血清中抗Ⅱ型胶原抗体和血清中的细胞因子浓度.鼠爪脱钙后行病理检查.采用两样本均数的t检验、χ~2检验进行统计学处理.结果 IL-33可使小鼠实验性的关节炎发病加重,致炎性细胞因子和抗Ⅱ型胶原抗体产生增多(P<0.05).PBS组与IL-33组的IgG2a型Ⅱ型胶原抗体为[(1.24±0.33)mg/L和(1.96±0.16)mg/L,P<0.05],而IgG1型抗Ⅱ型胶原抗体为[(1.1±0.4)ms/L和(1.7±0.4)mg/L,P<0.05).结论 IL-33是炎性关节病中的重要致炎因子.这一IL-1家族新成员是潜在的类风湿关节炎(RA)治疗靶点.
目的 探討新型細胞因子自細胞介素(IL)-33在膠原誘導性關節炎(CIA)髮病中的作用.方法 建它DBA/1小鼠的CIA模型.以牛Ⅱ型膠原(CⅡ)/完全福氏佐劑(CFA)免疫,從免疫後第21天開始每天註射IL-33或燐痠鹽緩遲液(PBS)共5 d.免疫後第28天取小鼠淋巴結細胞體外培養,培養上清的細胞因子濃度以酶聯免疫吸附試驗(ELISA)法檢測或Luminex檢測.同時檢測血清中抗Ⅱ型膠原抗體和血清中的細胞因子濃度.鼠爪脫鈣後行病理檢查.採用兩樣本均數的t檢驗、χ~2檢驗進行統計學處理.結果 IL-33可使小鼠實驗性的關節炎髮病加重,緻炎性細胞因子和抗Ⅱ型膠原抗體產生增多(P<0.05).PBS組與IL-33組的IgG2a型Ⅱ型膠原抗體為[(1.24±0.33)mg/L和(1.96±0.16)mg/L,P<0.05],而IgG1型抗Ⅱ型膠原抗體為[(1.1±0.4)ms/L和(1.7±0.4)mg/L,P<0.05).結論 IL-33是炎性關節病中的重要緻炎因子.這一IL-1傢族新成員是潛在的類風濕關節炎(RA)治療靶點.
목적 탐토신형세포인자자세포개소(IL)-33재효원유도성관절염(CIA)발병중적작용.방법 건타DBA/1소서적CIA모형.이우Ⅱ형효원(CⅡ)/완전복씨좌제(CFA)면역,종면역후제21천개시매천주사IL-33혹린산염완충액(PBS)공5 d.면역후제28천취소서림파결세포체외배양,배양상청적세포인자농도이매련면역흡부시험(ELISA)법검측혹Luminex검측.동시검측혈청중항Ⅱ형효원항체화혈청중적세포인자농도.서조탈개후행병리검사.채용량양본균수적t검험、χ~2검험진행통계학처리.결과 IL-33가사소서실험성적관절염발병가중,치염성세포인자화항Ⅱ형효원항체산생증다(P<0.05).PBS조여IL-33조적IgG2a형Ⅱ형효원항체위[(1.24±0.33)mg/L화(1.96±0.16)mg/L,P<0.05],이IgG1형항Ⅱ형효원항체위[(1.1±0.4)ms/L화(1.7±0.4)mg/L,P<0.05).결론 IL-33시염성관절병중적중요치염인자.저일IL-1가족신성원시잠재적류풍습관절염(RA)치료파점.
Objective To explore the role of a new cytokine interleukin (IL)-33 in collagen induced arthritis (CIA). Methods The murine model of CIA was employed. DBA/1 mice were immunized with C Ⅱ/CFA and challenged with the same dose of C Ⅱ in PBS on day 21. The mice were injected I.p daily with IL-33 or PBS for 5 clays from day 21. Lymphonodes were removed on day 28 after primary immunization and cultured. The concentrations of all eytokines of the supernatants were determined by ELISA or an 20-plex-mouse cyto-kine assay according to the manufacturer's instructions. Serum anti-C Ⅱ antibody and mice paw histology were. Also assessed. Two independent samples t test, chi-square test were used for statistical analysis. Results DBA/1 mice receiving IL-33 injection exhibited an exacerbated CIA both in terms of clinical evaluation and histological parameters. IL-17, IFN-γ, TNF-α, IL-5, IL-12, GM-CSF, MCP-1 and IP-10 productions were also elevated in IL-33 group (P<0.05). Similarly, mice in the IL-33 injection group had higher levels of anti-collagen antibodies compared with those of the controls. The concentrations of C Ⅱ-specific IgG2a were [(1.96±0.16) vs (1.24±sO.33) mg/L] (P<0.05), while IgG1 anti-C Ⅱ antibodies were [ (1.1±0.4) vs (1.7±0.4) mg/L] (P<0.05). Conclusion IL-33 is a critical pro-inflammatory cytokine for inflamm-atory joint disease. Thus this novel IL-1 supeffamily member represents a novel therapeutic target for rheumatoid arthritis ( RA ).
